The past 30 years has seen a trend towards conservative treatment of retinoblastoma.l2 Retinoblastoma is a highly radiosensitive tumour24 and external beam irradiation (EBI) has been used successfully since 1903.5 Although the majority of tumours regress after EBI, approximately 25% ofpatients require additional therapy because a tumour fails to regress or recurs, or because one or more new tumours arise.
Retinoblastoma tumours which respond to EBI rarely disappear completely and most leave a residual mass. The ophthalmoscopic appearance of successfully treated tumours has been classified into three regression patterns.6 In Type I regression the tumour assumes a glistening white appearance resembling cottage cheese (Fig  1) . In Type II the regressed tumour has a homogeneous, grey, translucent aspect which has been likened to fish flesh and which is difficult to distinguish from viable tumour (Fig 2) . Type III regression is a combination ofTypes I and II (Fig  3) . Occasionally, EBI is followed by complete disappearance of tumours less than 3 mm in diameter78 with minor changes in the retinal pigment epithelium as the only indication of the original tumour site. This pattern has been termed Type 0. Similar regression patterns have been described following radioactive scleral plaque therapy for retinoblastoma.9 After plaque therapy, total tumour destruction may result in the formation of a flat white scar when complete The distribution of regression patterns after EBI respectively for small, medium-sized, and large tumours is shown in Figure 5 . A Type I regression pattern was seen following EBI of retinoblastoma lesions of all sizes but most large tumours (36 of 46 or 78%) regressed in this pattern. Types II and III regression were seen Table 2 . By univariate analysis the pattern of regression was found to depend on the size of the tumour, on the method of treatment either by a whole eye or by a lens sparing approach, on the employment of an anterior or a lateral treatment portal, on the use of a total radiation dose of 350-390 Gy or one of 400-500 Gy, and on whether the chosen dose was given in 9-13 or in 20-22 fractions. When the data were examined in a multivariate fashion by discriminant analysis only tumour size, treatment method, and portal appeared as factors predicting regression pattern. The best coding of size was found to be one using a cut off at 6 mm. From the discriminant model including tumour 3 2 times that for a 6 mm lesion. The 95% confidence interval for this relative risk is (2 8, 3 5). Figure 9 shows KaplanMeier plots of the relapse-free interval following EBI for each tumour size category. Eight out of the 13 recurrences were following treatment of large tumours and the remaining five ofmediumsized tumours. None of the small tumours recurred. These observations are statistically significant (p<001) using Cox model regression analysis. Tumour size is independently related to the age at diagnosis (p=0 01). 
